Acumen Pharmaceuticals (ABOS) Research & Development (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Research & Development data on file, last reported at $16.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 34.76% year-over-year to $16.5 million; the trailing twelve-month figure through Mar 2026 stood at $96.1 million (down 9.86% YoY), and the FY2025 full-year result was $104.9 million, up 11.82% from the prior year.
• Research & Development declined to $16.5 million in Q1 2026, from $20.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $37.1 million in Q2 2025 to a low of $6.0 million in Q1 2022.
• A 5-year average of $17.0 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 361.61% in 2022 and tumbled 40.62% in 2025, its largest moves.
• Tracing ABOS's Research & Development over 5 years: stood at $10.7 million in 2022, then advanced by 23.7% to $13.3 million in 2023, then jumped by 160.05% to $34.6 million in 2024, then plunged by 40.62% to $20.5 million in 2025, then fell by 19.69% to $16.5 million in 2026.
• Business Quant data shows ABOS's Research & Development at $16.5 million in Q1 2026, $20.5 million in Q4 2025, and $22.0 million in Q3 2025.